🕵️ Climb BIO, Inc. ($CLYM)
SEC insider & ownership activity, last 12 months · CIK 1768446 · every row links its SEC filing
Over the last 12 months insiders sold $1.3M against $780K of open-market buying. Thomas Stephen Basil sold $879K through a 10b5-1 trading plan in 4 lots (Feb). No red-flag 8-Ks in the window.
Monthly net open-market insider flow, last 12 months (up = net buying)
Insider flow
1 buyer, $780K (3 lots) · 2 sellers, $1.3M (5 lots)
| Insider | Buys | Bought | Sells | Sold | Last |
|---|---|---|---|---|---|
| Thomas Stephen Basil | 0 | – | 4 | $879K | Feb 26, 2026 |
| RA Capital Management, L.P. | 3 | $780K | 0 | – | Jan 5, 2026 |
| Aoife Brennan | 0 | – | 1 | $407K | Jun 29, 2026 |
5%+ holders
| Holder | Stake | Class | Schedule | Event | |
|---|---|---|---|---|---|
| RA Capital Management, L.P. | 33.0% | 13D | Jul 2, 2026 | filing ↗ | |
| Peter Kolchinsky | 33.0% | 13D | Jul 2, 2026 | filing ↗ | |
| Rajeev Shah | 33.0% | 13D | Jul 2, 2026 | filing ↗ | |
| RA Capital Healthcare Fund, L.P. | 24.1% | 13D | Jul 2, 2026 | filing ↗ | |
| FMR LLC | 11.9% | 13G | Jul 8, 2026 | filing ↗ | |
| Abigail P. Johnson | 11.9% | 13G | Jul 8, 2026 | filing ↗ | |
| Pontifax Vi G.p. L.p. | 7.7% | 13G | Sep 18, 2025 | filing ↗ | |
| Pontifax Management 4 G.P. (2015) Ltd. | 7.7% | 13G | Sep 18, 2025 | filing ↗ | |
| Ran Nussbaum | 7.7% | 13G | Sep 18, 2025 | filing ↗ | |
| Tomer Kariv | 7.7% | 13G | Sep 18, 2025 | filing ↗ | |
| RA Capital Nexus Fund III, L.P. | 6.4% | 13D | Jul 2, 2026 | filing ↗ | |
| MPM Bioimpact LLC | 5.6% | 13G | Feb 17, 2026 | filing ↗ |
Planned insider sales (Form 144)
| Seller | Planned | Approx. sale date | |
|---|---|---|---|
| Aoife Brennan | $407K | Jun 29, 2026 | filing ↗ |
| Stephen Thomas | $318K | Feb 25, 2026 | filing ↗ |
| Stephen Thomas | $556K | Feb 12, 2026 | filing ↗ |
Material events (8-K)
| Item | Event date | |
|---|---|---|
| Officer/director changes (5.02) | Jun 29, 2026 | filing ↗ |
| Material agreement (1.01) | Jun 11, 2026 | filing ↗ |
| Other events (8.01) | Jun 11, 2026 | filing ↗ |
| Financial Statements and Exhibits (9.01) | Jun 11, 2026 | filing ↗ |
| Other events (8.01) | Jun 11, 2026 | filing ↗ |
| Officer/director changes (5.02) | Jun 5, 2026 | filing ↗ |
| Shareholder vote (5.07) | Jun 5, 2026 | filing ↗ |
| Financial Statements and Exhibits (9.01) | Jun 5, 2026 | filing ↗ |
| Other events (8.01) | Jun 5, 2026 | filing ↗ |
| Earnings (2.02) | May 7, 2026 | filing ↗ |
| Financial Statements and Exhibits (9.01) | May 7, 2026 | filing ↗ |
| Reg FD disclosure (7.01) | May 5, 2026 | filing ↗ |
| Financial Statements and Exhibits (9.01) | May 5, 2026 | filing ↗ |
| Material agreement (1.01) | Apr 27, 2026 | filing ↗ |
| Unregistered equity sale (3.02) | Apr 27, 2026 | filing ↗ |
| Other events (8.01) | Apr 27, 2026 | filing ↗ |
| Financial Statements and Exhibits (9.01) | Apr 27, 2026 | filing ↗ |
| Officer/director changes (5.02) | Apr 1, 2026 | filing ↗ |
| Earnings (2.02) | Mar 5, 2026 | filing ↗ |
| Financial Statements and Exhibits (9.01) | Mar 5, 2026 | filing ↗ |
| Reg FD disclosure (7.01) | Jan 8, 2026 | filing ↗ |
| Other events (8.01) | Jan 8, 2026 | filing ↗ |
| Financial Statements and Exhibits (9.01) | Jan 8, 2026 | filing ↗ |
| Other events (8.01) | Dec 31, 2025 | filing ↗ |
| Financial Statements and Exhibits (9.01) | Dec 31, 2025 | filing ↗ |
| Material agreement (1.01) | Dec 11, 2025 | filing ↗ |
| Unregistered equity sale (3.02) | Dec 11, 2025 | filing ↗ |
| Financial Statements and Exhibits (9.01) | Dec 11, 2025 | filing ↗ |
| Earnings (2.02) | Nov 6, 2025 | filing ↗ |
| Financial Statements and Exhibits (9.01) | Nov 6, 2025 | filing ↗ |